Engflag

Vectra

Quick links to important sections

Vectra

Vectra_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vectra

Quick Facts: Vectra (Valdecoxib)

Property Description
Active Ingredient Valdecoxib
Pharmacological Class Selective COX-2 Inhibitor (Coxib)
Form & Route Tablet, Oral Administration
Origin Synthetic, Sulfonamide Derivative
General Purpose Anti-inflammatory and Analgesic Action

What Type of Medicine is Vectra (Valdecoxib)?

Vectra is the trade designation for the active pharmaceutical ingredient Valdecoxib, a systemic compound belonging to the broad category of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). It is specifically classified as a selective Cyclooxygenase-2 (COX-2) Inhibitor, often referred to as a Coxib. This classification identifies a drug with a distinct mechanism compared to older, non-selective NSAIDs. For patients, this specialized status primarily establishes its suitability for conditions requiring powerful and consistent relief from inflammation and discomfort.

Composition, Form, and General Therapeutic Purpose

The medicine is a single-ingredient product where the sole active component is Valdecoxib, a compound that is entirely synthetic in origin and chemically identified as a sulfonamide derivative. The drug is consistently manufactured as a solid oral tablet intended for oral administration, distinguishing it from topical creams or injectable solutions found in related therapeutic classes. The general therapeutic purpose derived from its classification is the ability to suppress the synthesis of prostaglandins, which are key chemical mediators of symptomatic pain and inflammation. Valdecoxib exhibits potent anti-inflammatory, analgesic, and antipyretic properties. The core benefits derived from this focused action are comprehensive analgesia (relief from pain), antipyresis (fever reduction), and a significant anti-inflammatory effect.

What side effects are possible with Vectra?

Possible Side Effects and Safety Information

The safety profile of Vectra (Valdecoxib) is formally documented by regulatory authorities, classifying potential adverse reactions by frequency and affected organ system. This medicine, a selective COX-2 inhibitor and sulfonamide derivative, carries specific high-level safety warnings.

Serious Adverse Reactions

Official regulatory documentation identifies three major areas of serious risk. These include the potential for serious cardiovascular thrombotic events, such as Myocardial Infarction (heart attack) and Stroke. The label also highlights the risk of gastrointestinal ulceration, bleeding, and perforation, which can be life-threatening. Due to the drug's chemical structure, a third major risk involves Severe Cutaneous Adverse Reactions (SCARs), including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Common Adverse Reactions and Organ Systems

Adverse reactions that are frequently observed and categorized as Common in regulatory lists typically involve the Nervous System (e.g., headache, dizziness) and the Gastrointestinal System (e.g., dyspepsia, abdominal pain, flatulence). Peripheral edema (swelling) is also noted as a common effect.

Population-Specific Safety Considerations

The official labeling includes specific restrictions for certain groups. The medicine is contraindicated for treating pain following Coronary Artery Bypass Graft (CABG) surgery. Caution is advised for elderly patients and those with severe hepatic impairment. Furthermore, individuals with a known sulfonamide allergy may face an increased risk of severe cutaneous reactions. Regulatory documents also note that the risk of cardiovascular events may increase with the duration of use.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with the active ingredient Valdecoxib (Vectra) is primarily defined by the official regulatory documentation for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), detailing both acute manifestations and high-risk systemic complications.

Documented Overdose Presentations

Acute overdose typically involves generally reversible signs, including lethargy, drowsiness, nausea, vomiting, and epigastric pain. Regulators also document the potential for rare, severe systemic outcomes such as gastrointestinal bleeding, acute renal failure, respiratory depression, and coma. The NSAID class is associated with a risk of serious cardiovascular thromboembolic events. A specific regulatory note highlights that patients with moderate hepatic impairment may experience significantly increased plasma concentrations, which elevates the risk of toxicity in an overdose scenario.

When Immediate Medical Help is Required

Regulators mandate that immediate medical attention be sought for specific symptoms indicative of serious toxicity. This includes signs of a cardiovascular event, such as chest pain, sudden weakness, or slurred speech. Urgent help is also required for severe gastrointestinal symptoms, including vomiting blood, severe abdominal pain, or black, tarry stools. In all cases of suspected overdose, contacting emergency services is the required official procedure. Management is limited to symptomatic and supportive treatment, as no specific antidote is known.

Therapeutic Uses of Vectra

What Vectra Treats: Main Uses and Benefits

Vectra is commonly used to help with symptomatic relief across domains, including chronic arthritis and acute menstrual discomfort. The medicine is applied in addressing symptomatic relief in conditions characterized by periods of heightened symptoms such as Osteoarthritis, Rheumatoid Arthritis, and severe primary dysmenorrhea (menstrual cramping).

The medication may assist with addressing symptom clusters that interfere with daily comfort, including symptoms related to physical discomfort like persistent joint pain, swelling, and stiffness. It is considered relevant when supportive symptom management is appropriate in contexts involving heightened systemic burden, such as managing acute pain and intense discomfort.

“It supports the patient during difficult episodes by easing distress when symptoms become more noticeable.”

This approach contributes to easing the overall symptom load associated with long-term conditions and contributes to improved day-to-day comfort during symptomatic periods.

Quick Fact: Relief for Inflammation and Pain Vectra is commonly used to help with symptoms linked to inflammatory or irritative states that create noticeable physiological strain, supporting comfort during acute or episodic changes.

Eligibility and Restrictions for Use

The name Vectra refers to multiple distinct, regulated products. Official eligibility and exclusion criteria are specific to the type of product—either the Vectra DA multi-biomarker blood test or the Vectra F drug delivery device.

Official Eligibility Constraints

Product Populations Allowed Populations Excluded or Contraindicated
Vectra DA Test (Multi-Biomarker Disease Activity Score) Adult patients with a confirmed diagnosis of Rheumatoid Arthritis (RA). Individuals under 18 years of age or over 100 years of age (based on laboratory rejection criteria). The test is not intended to diagnose RA and must not be used for this purpose.
Vectra F Microsponge Device (Drug Delivery) Patients requiring localized delivery of medicinal substances to treat nasal disorders in the frontal ostia. Patients with a known allergy to shellfish, as the device contains materials derived from shellfish.

Regulatory documents define who can use the products by strictly limiting the target population and specifying mandatory exclusions. The Vectra DA test is restricted to use in adults after an RA diagnosis has already been established. The Vectra F Microsponge device carries a formal contraindication against its use in patients with a shellfish allergy, which must be followed due to its material composition.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile of Valdecoxib is defined by its involvement in the Cytochrome P450 (CYP) enzyme system, specifically as a substrate for CYP 3A4 and CYP 2C9, and an inhibitor of CYP 2C9 and CYP 2C19. These properties result in measurable changes in drug exposure for both Valdecoxib and co-administered agents.

Interaction Type Interacting Agent(s) Official Outcome
Increased Valdecoxib Exposure Fluconazole, Ketoconazole (CYP Inhibitors) Increased total plasma exposure (AUC).
Decreased Valdecoxib Exposure Phenytoin (CYP Inducer) Decreased total plasma exposure (AUC).
Increased Co-Drug Exposure/Effect Warfarin, Oral Contraceptives, Diazepam Increased exposure of the co-administered agent; increased INR with Warfarin.
Pharmacodynamic Effect ACE-Inhibitors, Diuretics May diminish antihypertensive or natriuretic effects.

Use is restricted in patients who have experienced allergic-type reactions (e.g., asthma, urticaria) after taking Acetylsalicylic acid or other NSAIDs. A regulatory constraint also prohibits use for pain management immediately following Coronary Artery Bypass Graft (CABG) surgery.

Regarding administration factors, specific studies indicate that food does not significantly affect the total extent of absorption, though it may delay the time to peak concentration. Co-administration with Antacids shows no significant effect on absorption. Additionally, in patients with moderate hepatic impairment, Valdecoxib plasma concentrations are significantly increased by 130%.

Mechanism of Action

How Vectra Works

Target and Ligand Interaction

Vectra is a human monoclonal antibody designed to selectively target the interleukin-17A ( IL-17 A) protein. As an antagonist, Vectra achieves its primary mechanism of action by binding to the soluble IL-17 A ligand with high affinity. This binding prevents the free IL-17 A ligand from interacting with its IL-17 R receptor complex on the surface of target cells.

Pathway Modulation and Cascade Effect

The blockade of IL-17 A suppresses the initiation of the IL-17 signaling pathway. Activation of this pathway normally leads to the nuclear translocation of transcription factors (e.g., NF-kappa B), which drive gene expression. Vectra's action modulates this process by reducing the transcription and subsequent secretion of key pro-inflammatory cytokines (such as IL-6 and TNF-alpha) and chemokines. By neutralizing the IL-17 A-driven inflammatory cascade, Vectra decreases the overall inflammatory load at the systemic and tissue level.

Dosage and Administration Information

Vectra (Valdecoxib) is administered orally as a film-coated tablet, available in 10 mg and 20 mg strengths. Dosing schedules vary based on the administration context.

For chronic use, such as the management of Osteoarthritis and Rheumatoid Arthritis, the standard starting dose is 10 mg once daily (QD). Consistent daily administration is required to maintain a steady plasma concentration. Should a greater systemic effect be necessary, the dose may be increased up to a maximum of 20 mg once daily.

For acute, short-term use, such as primary dysmenorrhea, the initial dose is 40 mg once daily, administered as required during the symptomatic period. The total daily intake on any subsequent day should not exceed 40 mg. The tablets may be taken with or without food to facilitate administration.

Specific administration constraints apply to distinct patient profiles. Older adults (age 65 and above) initiate treatment at the lowest recommended dose (10 mg QD), particularly if they have a low body weight. Furthermore, a dose reduction is required for patients with moderate hepatic impairment, where chronic use begins with 10 mg QD, and the acute daily dose must not exceed 20 mg. The use of Valdecoxib is not recommended for patients with severe hepatic impairment, and its safety and effectiveness have not been established in patients under the age of 18.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Vectra (Valdecoxib)

Evidence for Use in Chronic Arthritis: Osteoarthritis and Rheumatoid Arthritis

The research base for Valdecoxib includes studies of chronic arthritis, primarily built upon Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies were used in research exploring how symptoms change over time in adult populations with active Osteoarthritis (OA) and Adult Rheumatoid Arthritis (RA). Researchers monitored outcomes related to pain severity and outcomes reflecting daily functioning or activity level, utilizing standardized assessments like the WOMAC index for OA. Follow-up durations were typically intermediate-term, ranging up to six months.

For both conditions, studies reported how symptoms evolved in the observed populations. Findings describe patterns observed in the studies related to pain intensity and functional status compared to placebo groups over the studied time periods. The research highlights changes measured during the study period that were generally consistent with the patterns described for active comparators used in the studies.

Evidence for Use in Acute Pain and Primary Dysmenorrhea

Research exploring short-term symptom changes for Valdecoxib was conducted in conditions associated with acute or disruptive episodes, such as acute post-operative pain and Primary Dysmenorrhea (acute menstrual pain). The study designs included single-dose and very short-term multi-dose RCTs. For acute pain, studies monitored physiological strain or stress, including the patient-reported requirement for rescue opioid medication following procedures like surgery.

In these acute research scenarios, studies reported how symptoms evolved in the observed populations. Research highlights changes measured during the study period related to the time taken for relief to begin and the observed data related to the quantity of supplementary pain relief requested during the post-procedure period. Evidence contributes to understanding symptom patterns during these specific, brief episodes.

Gaps in the Research and Areas of Uncertainty

The evidence base provides insight into short-term changes but presents significant limitations in the broader evidence landscape. There is limited information for long-term outcomes (beyond six months) regarding the assessment of functional status and pain severity for chronic conditions. The evidence does not allow for established conclusions regarding the durability of symptom patterns over many years. Furthermore, the findings apply primarily to the specific populations studied, and data for other groups, such as children, remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Vectra (FAQ)

Q: How quickly is Vectra expected to start having an effect?

A: Studies on acute pain management have indicated that the medicine has a rapid onset of action. Symptom relief has been reported to occur as early as 30 minutes after taking a single dose. Consistent daily use, as described in regulatory documents, is necessary for maintaining an effect in chronic conditions.

Q: What happens if I miss taking a dose of Vectra?

A: Official patient instructions generally describe taking a missed dose as soon as it is remembered, unless it is close to the next scheduled dose. It is important that the total amount taken in a day does not exceed the maximum prescribed daily dose. This information is available in the authorized patient leaflet.

Q: What happens to Vectra in the body after it has exerted its effect?

A: After providing its anti-inflammatory and analgesic effect, the active ingredient is broken down in the liver through specific metabolic enzymes. Regulatory documents state that the inactive byproducts are then primarily eliminated from the body through the urine.

Q: Is it normal to feel [vague symptom, e.g., tired] when first starting Vectra?

A: Official product information lists common side effects that can affect general well-being, such as headache and dizziness. If these or other common effects occur, patients are advised to discuss them with a healthcare provider. The full range of common adverse reactions is documented in the product information.

Q: Are the side effects of Vectra temporary or do they last for a long time?

A: In clinical research, common side effects are frequently observed as temporary events. However, the official labeling warns that the risk of certain serious side effects, particularly cardiovascular events, is documented to increase with the duration of use.

Q: Can Vectra be taken while fasting or does it need food?

A: According to official instructions, the tablets may be taken with or without food. While food does not alter the total amount of medicine absorbed, official studies indicate that it may slightly delay the time it takes for the drug to reach its peak concentration in the blood.

Q: Are there any warnings about taking Vectra with alcohol?

A: Official guidelines describe that combining this class of medicine (NSAIDs) with alcohol may increase the documented risk of serious gastrointestinal issues, such as bleeding. Patients are advised to consult their healthcare provider about alcohol use.

Q: Can Vectra cause changes in mood or behavior?

A: The official list of common side effects focuses on effects on the nervous system, such as headache and dizziness. Patients using this class of medicine are typically advised to discuss any unusual changes in mood or behavior with a healthcare provider.

Q: Can the effectiveness of Vectra be measured by a blood test?

A: The name 'Vectra' refers to several distinct, regulated products. The Vectra DA Test is a specialized blood test used to monitor disease activity in adults with Rheumatoid Arthritis, but this test is not the medication itself or a measure of the drug's direct effectiveness.

Q: Is the research for Vectra still ongoing or has it concluded?

A: The initial clinical research supporting the drug's official approvals has been completed and published in regulatory documents. Official sources note that there is a limitation in evidence for long-term outcomes, specifically those extending beyond six months.

Q: Is Vectra the same type of medicine as [similar drug name]?

A: Vectra is classified as a selective Cyclooxygenase-2 (COX-2) Inhibitor. This classification places it in a specialized group of anti-inflammatory medicines that target the COX-2 enzyme, setting it apart from non-selective NSAIDs which affect both COX-1 and COX-2 enzymes.

Q: Does Vectra have any risk of addiction or dependence?

A: Vectra is classified as a selective COX-2 inhibitor and is not an opioid or a controlled substance. Official regulatory documents do not list addiction or physical dependence as a risk associated with its use.

Q: Is there a generic version of Vectra available?

A: The active ingredient in Vectra is Valdecoxib. Information regarding the availability of generic versions is regulated by health authorities, but this information may vary based on your specific location and current regulatory status.

Q: Are there any restrictions on driving or operating machinery while taking Vectra?

A: Official patient information advises caution. If side effects such as dizziness or tiredness (somnolence) are experienced, activities requiring alertness, such as driving or operating heavy machinery, should be avoided until the symptoms subside.

Q: Is Vectra used for children, and if so, what are the guidelines?

A: Official regulatory documents indicate that the safety and effectiveness have not been established in patients under the age of 18 years. Therefore, its use in the pediatric population is generally restricted.

Q: Where can I find the official patient leaflet (PIL) for Vectra?

A: The official patient leaflet (known as the Patient Information Leaflet or Medication Guide) is provided when the medicine is dispensed. You can also access regulatory documents online through governmental health portals such as the FDA DailyMed database.

Q: Can Vectra be used to treat conditions other than the main ones listed?

A: The medicine is only officially approved by regulatory authorities for the specific conditions detailed in the Indications section of the official labeling, such as Osteoarthritis, Rheumatoid Arthritis, and Primary Dysmenorrhea.

Q: Does Vectra affect fertility or planning to have children?

A: Official warnings state that the medicine may impair female fertility and is generally described as not recommended for women who are attempting to conceive. This effect is described as reversible upon stopping the medicine.

Q: What kind of monitoring is typically done when a person starts taking Vectra?

A: Regulatory documents describe that monitoring, due to documented risks, may include regular checks for signs of cardiovascular issues, gastrointestinal bleeding, and severe skin reactions. Caution is also advised regarding potential for fluid retention.

Q: Are there alternatives to Vectra if I cannot tolerate the side effects?

A: Clinical trials for Vectra often compare its effects to those of other conventional NSAIDs (Nonsteroidal Anti-Inflammatory Drugs), such as naproxen. These official comparisons confirm the existence of other regulated treatments within the same therapeutic class.

Q: Does Vectra interact with birth control pills?

A: Official documentation lists an interaction with Oral Contraceptives. Co-administration may lead to an increased exposure of the hormonal contraceptive, which is described as potentially impacting its effects.

Q: Can Vectra be used during pregnancy or while breastfeeding?

A: Use during pregnancy is generally not recommended, especially during the third trimester, due to documented risks to the developing fetus. The manufacturer recommends a decision be made to discontinue nursing or discontinue the drug while breastfeeding.

How should Vectra be stored and disposed of?

How to Store and Dispose of Vectra (Valdecoxib) Tablets

Official regulatory documents define strict conditions for the storage and disposal of Valdecoxib tablets.

Storage Requirements

  • Temperature and Environment: Store at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). The medication must be kept away from excess heat, moisture, direct light, and must not freeze.
  • Container and Protection: The tablets must be stored in a closed container and securely kept out of the reach of children.
  • Stability: Do not keep or use outdated medicine past its official expiration date.

Disposal Instructions

  • Environmental Protection: Due to its classification as an environmental hazard, the medicine must not be allowed to reach the sewage system. Do not throw the tablets away with household garbage.
  • Official Discarding: Dispose of any unused or expired product as instructed by a healthcare professional or pharmacist to ensure proper controlled disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Vectra found in:

A-Z Index: